Home / Market News / $AMGN
benzinga Corporate Catalyst Impact 55/100 ● positive

RBC Capital Maintains Outperform on Amgen, Raises Price Target to $430

Oct 8, 2026, 2:39 PM UTC · Primary ticker $AMGN

RBC Capital's analyst Luca Issi reiterated an 'Outperform' rating on Amgen and increased its price target from $400 to $430. This indicates a positive outlook from a prominent analyst, which could provide a modest boost to investor confidence and potentially the stock price.

RBC Capital analyst Luca Issi maintained an 'Outperform' rating on Amgen and raised the price target from $400 to $430. This action signals continued confidence in Amgen's future performance and valuation from a significant financial institution. For traders, this could lead to short-term positive sentiment and potentially a slight upward movement in Amgen's stock price as investors react to the revised target. The long-term implications depend on whether Amgen's fundamentals align with this increased valuation. A key opportunity for traders is to consider this analyst upgrade as a potential buy signal, though it's important to note that analyst ratings are just one factor in investment decisions.

$AMGN positive Analyst price target increase
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.